Semaglutide Titration: Why Dose Escalation Is Slow
Released · Last reviewed
Semaglutide is escalated slowly — typically starting at 0.25mg weekly and increasing every four weeks — to reduce gastrointestinal side effects. Rushing the schedule increases nausea and dropout without improving results.
- Standard escalation starts at 0.25mg weekly, rising every ~4 weeks.
- Slow titration reduces nausea and GI side effects.
- The maintenance dose for weight management is 2.4mg weekly.
- Rushing titration increases side effects without better outcomes.
The standard schedule
For weight management, semaglutide (Wegovy) follows a defined escalation: 0.25mg weekly for four weeks, then 0.5mg, then 1mg, then 1.7mg, reaching the 2.4mg maintenance dose over about 16-20 weeks. Each step lasts roughly four weeks.
This gradual increase is deliberate. Starting at a low dose and stepping up slowly gives the body time to adapt to the medication's effects on the gut.
The diabetes products (Ozempic) use a similar principle with somewhat different target doses.
Why slow titration matters
The main reason for slow escalation is tolerability. GLP-1 medications commonly cause nausea, and less often vomiting, diarrhea, or constipation, especially when starting or increasing the dose. A gradual increase substantially reduces the severity of these effects.
Rushing the schedule — jumping to a high dose quickly — increases the likelihood of significant nausea and is a common reason people stop treatment. It does not produce faster or better weight loss.
The escalation schedule is therefore about keeping people on the medication long enough to benefit, not about caution for its own sake.
| Weeks | Weekly dose |
|---|---|
| 1-4 | 0.25mg |
| 5-8 | 0.5mg |
| 9-12 | 1mg |
| 13-16 | 1.7mg |
| 17+ | 2.4mg (maintenance) |
Titration and compounded products
Compounded semaglutide may not follow the same standardized dosing as the approved product, and dose accuracy depends on the compounding pharmacy. This is one of the practical risks of compounded formulations: the titration you receive may differ from the studied schedule.
Some compounded programs offer non-standard dosing or microdosing that has no basis in the trial evidence. The approved titration schedule exists because it was studied; deviations have not been.
If you are on a compounded product, your titration should still be directed by your clinician, following approved-product principles as closely as the formulation allows.
Individual variation
Not everyone tolerates the standard schedule at the same pace. Some people need to stay longer at a given dose before increasing; others tolerate escalation well. The schedule is a default, not a mandate.
If side effects are significant at a dose increase, the appropriate response is often to hold at the current dose longer rather than push forward. This is a clinical judgment.
Communicate side effects to your clinician so the schedule can be adjusted to you.
| Faster escalation | Result |
|---|---|
| Jump to high dose | More nausea, more dropout |
| Standard schedule | Better tolerability, same efficacy |
The bottom line
Semaglutide is titrated slowly — starting at 0.25mg and rising every four weeks to a 2.4mg maintenance dose — specifically to reduce gastrointestinal side effects and keep people on treatment.
Rushing the schedule increases nausea and dropout without improving results. Individual pace varies, and side effects should guide adjustments.
This is educational information; your titration should be directed by your clinician.
Frequently asked questions
Why is semaglutide started at a low dose?
To reduce gastrointestinal side effects like nausea. A gradual increase lets the body adapt and keeps people on treatment.
What is the maintenance dose?
For weight management, 2.4mg weekly, reached over about 16-20 weeks of escalation.
Can I escalate faster to lose weight quicker?
No. Faster escalation increases side effects without improving results, and often causes people to stop treatment.
Does compounded semaglutide follow the same schedule?
Not necessarily. Dose accuracy depends on the pharmacy, and some programs use non-standard dosing without trial support. Titration should still be clinician-directed.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, PIONEER, FLOW trial publications.
- ClinicalTrials.gov registrations and prescribing information.
- Evidence policy and ledger: evidence policy.
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $49 to $279 a month across the 22 programmes we priced on October 15, 2026, with a median of $99. The spread is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $87 and Eden at $99; lower stickers come with a sale, a prepaid year or a membership. Half the programmes sit below $99 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Two programmes printed a semaglutide microdose price on October 15, 2026 (Shed from $149, Noom Med $179); NexLife's microdose semaglutide has cost the same as its standard plan since November 8, 2026 ($109 a month month-to-month). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How semaglutide is kept current
On October 15, 2026, compounded semaglutide ran $49 to $279 a month across the 22 programmes we priced. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose semaglutide spans $49 to $279 a month across the 22 programmes we priced on October 15, 2026, a spread of $230.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed semaglutide cheaper?
Because it is less medicine. On October 15, 2026, Shed listed a semaglutide microdose from $149 a month and Noom Med at $179 after a $79 start. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What does compounded semaglutide cost per month in October 2026?
As of October 15, 2026, the 22 compounded semaglutide programs we could price on their own pages charge between $49 and $279 a month at their lowest all-in rate, with a median of $99, counting any required membership and the cheapest plan term each program prints. The low end is made of sale and "as low as" prices: WellMedr's fall sale and NextMeds both start at $49. Standing month-to-month rates with no membership start at $87 (Mondae) and $99 (Eden). Compounded semaglutide is not FDA-approved.
What does compounded semaglutide normally cost?
$49 to $279 a month at the lowest all-in rate across the 22 programs we priced on October 15, 2026, with a median of $99. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.